3. We’re not about theoretical excitement
Life science companies are not ready for AI — one of the hot takes from JPM24. The anticipation for AI to transform the life science industry was up for discussion — is the enthusiasm for AI overshadowing readiness? With an imperfect healthcare ecosystem, how can hospitals, care teams, and emerging Rx players ultimately use AI to impact patients today? Only when all of these elements are connected will AI even begin to be intelligent.
We’re not about theoretical excitement — Viz.ai has been integrated into 1,500 healthcare systems generating real-world diagnostic insights today.?
Subscribe to this newsletter to stay in the loop and receive an exclusive bi-monthly edition directly to your inbox by subscribing here.
?? The Latest
?? Watch
Dr Chris Mansi was joined by Greg Meyers of 百时美施贵宝 to discuss how we're 'Unlocking AI’s Potential in Pharma'. AI’s role in catalyzing patient care coordination was the theme at the heart of the discussion.
?? Read
?? "It will become increasingly likely that AI will play an invaluable role in providing second opinions with automated, System 2 machine-thinking." Looking to the future of medicine, Eric Topol, MD outlines how with more applications of AI in the clinic will move us "Toward the eradication of medical diagnostic errors" — read Dr. Topol's latest essay published in Science Magazine .
?? Vizion
?? "AI is applicable and has the potential to add value to cardiac imaging at every step along the patient journey,” said Kate Hanneman MD, MPH, associate professor and vice chair of research, University of Toronto, Canada to Medscape. This statement was in response to the American Heart Association’s statement, Value Creation Through Artificial Intelligence and Cardiovascular Imaging, published in Circulation.
We’re keeping an eye on upcoming guidelines for ATTR-CM detection from the American Society of Nuclear Cardiology (ASNC). Standardization guidelines will increase demand on imaging. “Driven by the emergence of drugs designed to treat the condition, the need for accurate and comprehensive imaging techniques has become paramount,” said Cardiology Business. Early detection of ATTR-CM is the key to preventing progressive disease and improving patient outcomes and quality of life. Ongoing monitoring and timely communication between specialists will be critical for adherence of these new therapies. AI models for cardiac amyloidosis could make a world of difference.
?? With significant pressure to cut costs and achieve efficiency — hospitals are being advised to look to digital solutions. “We see rising costs being a massive, massive theme. How do you use AI? And how do you start to streamline internal operations to reduce your operating expense? There are ways of doing that, AI is one of 100 different ways,” said Benjamin Baenen , partner of healthcare and life sciences at West Monroe . Further, healthcare companies are ignoring buzz around AI solutions and looking to find the right AI partners with “proven customer backlogs, satisfied customers, long tenured customers”.
The World Economic Forum explored how AI can transform patient care and treatment. Read this in-depth dive into how “AI is reshaping the way we approach patient care and treatment decisions.”
??An exciting window of insight from Eric Topol, MD into how AI is revolutionizing medicine — from keyboard liberation, seamless care coordination, accurate disease diagnosis, and the 'gift of time'. Watch Dr. Eric Topol, MD on the TED stage as he discusses the question, 'Can AI catch what doctors miss?'. Here at Viz.ai , we're especially excited to be playing our part in medicine's transformation that will ultimately make a difference for both patients and doctors.
?? AI predictions for 2024 and more to say on AI in Healthcare in 2024. Read insights from Healthcare AI experts and thought leaders on what they think 2024 will bring.
“EHR messaging interrupts healthcare providers and contributes to clinician burnout.” This study's authors recommend that Epic's secure chat feature not be used for "urgent and emergent issues." Healthcare systems are looking to AI for efficiency when it comes to HCP attention. Beckers added a brief summary of the paper. By combining only the relevant outputs with the EHR with AI-powered triage, Viz.ai is empowering care providers to coordinate care efficiently.???
???? ?? Blood tests combined with PET imaging was clinically shown to be highly accurate at detecting Alzheimer’s diseases, this paper/clinical study published in JAMA Neurology, ?Affirms High Diagnostic Accuracy of ALZpath's pTau217 Test in Identifying Amyloid and Tau in the Brain. The increased demand to identify Alzheimer’s disease early and to ensure upkeep of periodic monitoring for amyloid related imaging abnormalities (ARIA) on MRI scans. AI at the point of care today will ensure HCPs can make the best next action for their patients. This is where Viz.ai excels.
?? Viz News
Viz.ai is now adopted in 1,500+ US hospitals, with 45,000 healthcare providers using our AI-powered platform at the point-of-care — and we have collaborations with 7 top life science companies!
?? The 2nd edition of NEJM AI is here! This edition includes an overview of how the journal is committed to the publication of "clinical-grade evidence needed to improve patient care with AI." We’re a proud sponsor of this journal and we strongly support the exploration of the cutting-edge applications of artificial intelligence and machine learning in clinical medicine. Check out the latest edition of NEJM AI.
Forbes spotlighted our remarkable journey, tracking the evolution from an AI startup transforming stroke care, to our venture into generative AI, and current expansion beyond the hospital to collaborate with the world’s leading pharma companies to deliver AI-powered insights directly to HCPs at the point of care.
?? By the Numbers
领英推荐
102
?? Cardiology clinical AI algorithms are now cleared by the U.S. Food and Drug Administration (FDA). Read why experts say this is just the beginning.
#2
Cardiology is now ranked as one of the top clinical AI algorithms cleared by the FDA. Read the FDA-issued report.
Not only are more and more cardiology algorithms being approved by the FDA, they are now part of the clinical guideline framework, with ACC/AHA 2021 Chest Pain Guidelines recommending the use of AI-driven fractional flow reserve hemodynamic flow measurements derived from noninvasive CT imaging (FFR-CT). The article highlights how "many cardiac imaging experts say AI is no longer a science project and it is impacting real, everyday patient outcomes now.”
?? Events
Dr Chris Mansi of Viz.ai was joined by Greg Meyers of 百时美施贵宝 on the Fierce Pharma stage at #JPM24 to discuss how we're 'Unlocking AI’s Potential in Pharma'. AI’s role in catalyzing patient #CareCoordination was at the heart of the discussion — ?? Tune in now.
Coming up...
?? International Stroke Conference | February 7 - 8
Meet with Bill Stadtlander ?to discuss how Viz.ai can accelerate your market development efforts #ISC24
??? Charlotte’s AI Web of Clinical Workflows ViVE , February 26 Jayme Strauss RN,MSN,MBA,SCRN , Chief Clinical Officer at Viz.ai will be speaking #ViVE2024
?? Healthcare Information and Management Systems Society | March 11 - 15
Meet with #TeamViz @ #HIMSS24
?? Reuters Events: Pharma USA 2024 | March 26 - 27
Join Ankit Agarwal , Nina Binetti , and Aditya Jagannathan in Philly #REpharmaUSA
Unite behind a shared vision – define our AI future | March 26 @ 5:50 - 6:30 pm Viz.ai ’s VP of Marketing Nina Binetti will be joined by an expert panel of pharma leaders to “Unite behind a shared vision – define our AI future”.
?? American College of Cardiology (ACC) | April 6 - 8
Meet Nina Binetti , Tom Krohn , and Bill Stadtlander at #ACC24
??? Contributors
Get in touch with Tom Krohn and Sherie Zhou
Copyright ? 2024 Viz.ai
548 Market St., # 21826, San Francisco, CA 94104
Between issues, keep current with the latest updates from Viz.ai by following us on LinkedIn and by subscribing to the insider version of Innovizion, sent bi-monthly directly to your inbox from us.
That sounds like a leap forward in healthcare innovation! ?? As Steve Jobs once said, "Innovation distinguishes between a leader and a follower." Subscribed and excited to see how point-of-care AI shapes the future! ???
Co-Founder of Altrosyn and DIrector at CDTECH | Inventor | Manufacturer
9 个月You mentioned the Innovizion newsletter focusing on the future of healthcare with a compelling argument for point-of-care AI. Analyzing historical trends, the integration of AI in healthcare has shown exponential growth, enhancing diagnostics and patient care. Drawing parallels with notable advancements, such as IBM Watson's contributions to cancer treatment, your emphasis on point-of-care AI aligns with a transformative approach to personalized medicine. In this context, considering the dynamic landscape of healthcare technologies, what key ethical considerations do you believe should guide the widespread adoption of point-of-care AI, balancing innovation and patient well-being?